Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 20/20 | 0.55 |
| ▸ | PTGDR | Q13258 | 15/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.46 |
| ▸ | PTGFR | P43088 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2922261 | 0.84 | TBXA2R (0.55) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL990995 | 0.83 | TBXA2R (0.73) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL1254339 | 0.82 | TBXA2R (0.54) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL4321145 | 0.77 | TBXA2R (0.62) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL4318470 | 0.77 | TBXA2R (0.76) | TBXA2RPTGDR | |
| SCHEMBL4321521 | 0.72 | TBXA2R (0.75) | TBXA2RPTGDR | |
| SCHEMBL12923780 | 0.69 | TBXA2R (0.61) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL3148394 | 0.67 | TBXA2R (0.73) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL991162 | 0.64 | TBXA2R (1.00) | TBXA2RPTGDR | |
| SCHEMBL991147 | 0.64 | PTGDR (1.00) | TBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874301-A4 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1874301-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1855649-A2 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006113150-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006089309-A2 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-1624871-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004103370-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS | MERCK & CO., INC. (US) | 2004-12-02 | — | — | WO | disclosed |